Dashboard
Manage Tickers

GALTGALECTIN THERAPEUTICS INC

Nasdaq galectintherapeutics.com


$ 3.48 $ 0.13 (3.89 %)    

Monday, 06-May-2024 15:58:27 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 439.97 $ 4.77 (1.1 %)
DIA $ 388.40 $ 1.68 (0.43 %)
SPY $ 516.34 $ 5.28 (1.03 %)
TLT $ 90.16 $ 0.35 (0.39 %)
GLD $ 215.21 $ 2.24 (1.05 %)
$ 3.47
$ 3.30
$ 0.00 x 0
$ 0.00 x 0
$ 3.30 - $ 3.59
$ 1.28 - $ 4.27
151,201
na
208.75M
$ 0.85
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-29-2024 12-31-2023 10-K
2 11-13-2023 09-30-2023 10-Q
3 08-14-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-30-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-15-2022 06-30-2022 10-Q
8 05-16-2022 03-31-2022 10-Q
9 03-31-2022 12-31-2021 10-K
10 11-15-2021 09-30-2021 10-Q
11 08-16-2021 06-30-2021 10-Q
12 05-17-2021 03-31-2021 10-Q
13 03-31-2021 12-31-2020 10-K
14 11-09-2020 09-30-2020 10-Q
15 08-10-2020 06-30-2020 10-Q
16 05-11-2020 03-31-2020 10-Q
17 03-16-2020 12-31-2019 10-K
18 11-12-2019 09-30-2019 10-Q
19 08-09-2019 06-30-2019 10-Q
20 05-10-2019 03-31-2019 10-Q
21 03-06-2019 12-31-2018 10-K
22 11-13-2018 09-30-2018 10-Q
23 08-14-2018 06-30-2018 10-Q
24 05-11-2018 03-31-2018 10-Q
25 03-29-2018 12-31-2017 10-K
26 11-07-2017 09-30-2017 10-Q
27 08-14-2017 06-30-2017 10-Q
28 05-15-2017 03-31-2017 10-Q
29 03-28-2017 12-31-2016 10-K
30 11-08-2016 09-30-2016 10-Q
31 08-09-2016 06-30-2016 10-Q
32 05-10-2016 03-31-2016 10-Q
33 03-15-2016 12-31-2015 10-K
34 11-09-2015 09-30-2015 10-Q
35 08-10-2015 06-30-2015 10-Q
36 05-11-2015 03-31-2015 10-Q
37 03-18-2015 12-31-2014 10-K
38 11-10-2014 09-30-2014 10-Q
39 08-07-2014 06-30-2014 10-Q
40 05-13-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

galectin-therapeutics-and-2-other-penny-stocks-insiders-are-buying
Galectin Therapeutics And 2 Other Penny St...
04/23/2024 10:53:53

hc-wainwright--co-reiterates-buy-on-galectin-therapeutics-maintains-11-price-target
HC Wainwright & Co. Reiterates Buy on Gale...
04/09/2024 15:57:49

HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price ta...

galectin-therapeutics-highlights-outcome-of-fifth-data-and-safety-monitoring-board-meeting-for-navigate-phase-2b3-study
Galectin Therapeutics Highlights Outcome O...
04/09/2024 13:26:30

Data and Safety Monitoring Board (DSMB) recommends the continuation, without modifications, of the adaptive Phase 2b/3 NAVIGATE...

12-health-care-stocks-moving-in-fridays-intraday-session
12 Health Care Stocks Moving In Friday's I...
04/05/2024 16:31:08

hc-wainwright--co-reiterates-buy-on-galectin-therapeutics-maintains-11-price-target
HC Wainwright & Co. Reiterates Buy on Gale...
04/01/2024 16:21:47

HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price ta...

galectin-therapeutics-q3-earnings-insights
Galectin Therapeutics: Q3 Earnings Insights
11/13/2023 13:50:06

galectin-therapeutics-204m-of-cash-and-cash-equivalents-and-30m-remaining-available-under-a-60m-line-of-credit-provided-by-its-chairman-is-sufficient-cash-to-fund-currently-planned-operations-and-rd-activities-through-at-least-december-31-2024
Galectin Therapeutics' $20.4M Of Cash And ...
11/13/2023 13:23:55

galectin-therapeutics-q3-eps-024-misses-016-estimate
Galectin Therapeutics Q3 EPS $(0.24) Misse...
11/13/2023 13:23:17

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate ...

galectin-therapeutics-reports-the-outcome-of-the-fourth-data-and-safety-monitoring-board-meeting-for-navigate-its-seamless-adaptive-phase-2b3-study-of-belapectin-in-patients-with-portal-hypertension-caused-by-non-alcoholic-steatohepatitis-live
Galectin Therapeutics Reports The Outcome ...
10/03/2023 12:02:57

Galectin Therapeutics, Inc.

galectin-therapeutics-to-present-update-on-its-belapectin-liver-cirrhosis-program-at-the-20th-edition-of-discovery-on-target-meeting-in-boston-september-25-28-2023
Galectin Therapeutics To Present Update On...
09/26/2023 12:07:59

Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced it wil...

hc-wainwright--co-reiterates-buy-on-galectin-therapeutics-maintains-11-price-target
HC Wainwright & Co. Reiterates Buy on Gale...
08/15/2023 11:17:24

HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price ta...

galectin-therapeutics-q2-eps-015-beats-021-estimate
Galectin Therapeutics Q2 EPS $(0.15) Beats...
08/14/2023 12:21:00

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of...

galectin-therapeutics-and-3-other-stocks-under-2-insiders-are-buying
Galectin Therapeutics And 3 Other Stocks U...
07/21/2023 11:24:34

The Dow Jones closed higher by more than 150 points on Thursday. When insiders purchase or sell shares, it indicates their conf...

hc-wainwright--co-reiterates-buy-on-galectin-therapeutics-maintains-11-price-target
HC Wainwright & Co. Reiterates Buy on Gale...
05/17/2023 10:25:10

HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price ta...

galectin-therapeutics-q1-eps-019-beats-021-estimate-the-company-had-178-million-of-cash-and-cash-equivalents-and-expects-that-it-will-require-more-cash-to-fund-operations-after-december-31-2024
Galectin Therapeutics Q1 EPS $(0.19) Beats...
05/15/2023 12:18:41

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of...

galectin-therapeutics-reports-fy22-eps-loss-of-065-down-from-052-loss-a-year-ago
Galectin Therapeutics Reports FY22 EPS Los...
03/30/2023 11:59:26

galectin-therapeutics-reported-the-outcome-of-its-third-data-and-safety-monitoring-board-meeting-for-navigate-phase-2b3-study-of-belapectin-for-liver-cirrhosis-caused-by-nash-interim-data-from-the-phase-2b-portion-is-expected-in-q4-of-2024
Galectin Therapeutics Reported The Outcome...
03/16/2023 12:08:29

The objective of this third independent DSMB was to further review the emerging tolerance and safety profiles of belapectin. Ba...

hc-wainwright--co-reiterates-buy-on-galectin-therapeutics-maintains-11-price-target
HC Wainwright & Co. Reiterates Buy on Gale...
03/03/2023 16:50:13

HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price ta...

galectin-therapeutics-provides-final-randomization-status-of-navigate-its-seamless-adaptive-phase-2b3-study-of-belapectin-in-patients-with-liver-cirrhosis-caused-by-non-alcoholic-steatohepatitis
Galectin Therapeutics Provides Final Rando...
03/02/2023 13:27:40

 Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, announced that in lat...

7m-bet-on-this-healthcare-stock-check-out-these-4-penny-stocks-insiders-are-buying
$7M Bet On This Healthcare Stock? Check Ou...
02/22/2023 13:40:00

The Dow Jones closed lower by around 700 points on Tuesday. When insiders purchase or sell shares, it indicates their confidenc...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION